Wordt geladen...
Use of bevacizumab in recurrent glioblastoma
Glioblastoma (GBM) is the most common adult primary brain neoplasm. Despite advances in treatment, GBM continues to be associated with considerable morbidity and mortality as compared with other malignancies. Standard treatment for GBM results in survival of 12.9 months (95% CI: 12.3–13.7 months) wi...
Bewaard in:
| Gepubliceerd in: | CNS Oncol |
|---|---|
| Hoofdauteurs: | , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Future Medicine Ltd
2015
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6088330/ https://ncbi.nlm.nih.gov/pubmed/25906439 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/cns.15.8 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|